	US 12,109,237 B2
	S309 chimeric antigen receptors and methods of use
Dongfang Liu, Millburn, NJ (US); Minh Ma, New Brunswick, NJ (US); and Saiaditya Badeti, New Brunswick, NJ (US)
Assigned to Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed by Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed on Dec. 14, 2021, as Appl. No. 17/551,006.
Claims priority of provisional application 63/125,820, filed on Dec. 15, 2020.
Prior Publication US 2022/0184125 A1, Jun. 16, 2022
Int. Cl. A61K 35/17 (2015.01); A61P 31/14 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/10 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 35/17 (2013.01) [A61P 31/14 (2018.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/7151 (2013.01); C07K 16/10 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)]

16 Claims

1. A method of treating a subject having or suspected of having a coronavirus infection, comprising administering to the subject an effective amount of a modified immune cell comprising a chimeric antigen receptor comprising at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1, wherein the chimeric antigen receptor comprises an antigen binding domain comprising the variable heavy chain (VH) domain complementarity determining region 1 (CDR1), CDR2 and CDR3 amino acid sequences of amino acid positions 47-54, 72-79, and 118-137 of SEQ ID NO: 1, respectively, and the variable light chain (VL) domain CDR1, CDR2 and CDR3 amino acid sequences of amino acid positions 195-201, 219-221, and 258-265 of SEQ ID NO: 1, respectively.